Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Decidual-like NK Cells for Infertility
NCT06821685Phase 1Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous decidual-like natural killer cells in infertility, recurrent spontaneous abortion (RPL), Repeated Implantation Failure (RIF) and 2 more, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Improvement rate of NK cells at 6 months. Started Feb 2025; status: recruiting.
02
Drugs
autologous decidual-like natural killer cells
03
Conditions
infertilityrecurrent spontaneous abortion (RPL)Repeated Implantation Failure (RIF)preeclampsiafetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT06821685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821685.